Physician profile
Daniel Gossett
NPI 1588980072
$35,715.11
in general payments reported to CMS, 2019-2025
67 companies · $2,369 in 2025
The $2,369 reported for 2025 was more than what 80% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,830 · 2020: $1,297 · 2021: $3,011 · 2022: $2,349 · 2023: $10K · 2024: $15K · 2025: $2,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $7,882 · Travel and Lodging: $646 · Education: $2.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,696.08 |
| Food and Beverage | $7,882.39 |
| Travel and Lodging | $646.22 |
| Education | $2.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immedica Pharma US, INC. | $15,935.28 | 2022-2025 | Ztalmy |
| Biomarin Pharmaceutical INC. | $5,118.44 | 2019-2023 | Brineura |
| Ucb, INC. | $1,510.98 | 2019-2025 | Fintepla, Briviact, Rystiggo |
| Ironshore Pharmaceuticals INC. | $1,092.04 | 2019-2023 | Jornay Pm |
| Natus Medical Incorporated | $1,011.54 | 2019-2021 | |
| Eisai INC. | $1,007.57 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $891.28 | 2019-2025 | Qelbree, Qelbree |
| Livanova USA, INC. | $817.48 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Jazz Pharmaceuticals INC. | $710.43 | 2019-2025 | |
| Neurelis, INC. | $688.34 | 2020-2025 | Valtoco |
| Tris Pharma INC | $555.61 | 2019-2023 | Dyanavel Xr |
| Corium, LLC | $461.14 | 2021-2025 | Azstarys |
| Sk Life Science, INC. | $446.84 | 2021-2024 | Xcopri |
| Neos Therapeutics, LP | $431.54 | 2019-2023 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Sunovion Pharmaceuticals INC. | $384.16 | 2019-2021 |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $342.99 | 2024-2025 | Nuplazid, Daybue |
| Aquestive Therapeutics, INC. | $294.28 | 2019-2022 | |
| Argenx US, INC. | $272.86 | 2024-2025 | Vyvgart Hytrulo |
| Merz Pharmaceuticals, LLC | $255.88 | 2024-2025 | Xeomin |
| Takeda Pharmaceuticals U.S.A., INC. | $237.72 | 2021-2025 | Hyqvia |
| Adlon Therapeutics L.P. | $212.42 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $187.33 | 2023-2024 | Aptiom |
| Abbvie INC. | $186.34 | 2023-2025 | |
| Zogenix INC. | $179.56 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $176.68 | 2024-2025 | Ingrezza |
| Biohaven Pharmaceuticals, INC. | $165.52 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $163.73 | 2024-2025 | Austedo Xr, Austedo Xr |
| Aprecia Pharmaceuticals, LLC | $160.50 | 2020-2023 | Spritam |
| Biogen, INC. | $141.00 | 2020-2025 | Skyclarys, Tysabri |
| Ipsen Biopharmaceuticals, INC | $129.17 | 2023-2024 | Dysport |
| Tg Therapeutics, INC. | $120.80 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $85.77 | 2024 | Ultomiris, Soliris |
| Catalyst Pharmaceuticals, INC. | $83.57 | 2023-2025 | Fycompa |
| Octapharma USA, INC. | $73.60 | 2024-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Grifols USA, LLC | $73.58 | 2024-2025 | Gamunex-C |
| Arbor Pharmaceuticals, INC. | $65.03 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $59.62 | 2020-2024 | Rytary |
| Shire North American Group INC | $58.57 | 2019 | |
| Collegium Pharmaceutical, INC. | $58.56 | 2025 | Jornay Pm |
| Allergan, INC. | $52.78 | 2020-2021 | |
| Avion Pharmaceuticals | $50.50 | 2023 | Methylphenidate Hydrochloride |
| Genzyme Corporation | $49.29 | 2019 | |
| Lundbeck LLC | $47.53 | 2024-2025 | Vyepti |
| Ns Pharma, INC. | $46.89 | 2023 | Viltepso |
| Travere Therapeutics, INC. | $46.29 | 2019-2023 | Cholbam |
| Ptc Therapeutics, INC. | $42.59 | 2021-2022 | |
| Cranial Technologies, INC | $41.45 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $40.61 | 2024 | Purified Cortrophin Gel |
| Kedrion Biopharma, INC. | $40.18 | 2024 | Gammaked, Kedrab, Koate |
| Springworks Therapeutics, INC. | $35.34 | 2025 | Gomekli |
| Biohaven Pharmaceutical Holding Company LTD. | $32.32 | 2022 | |
| Sarepta Therapeutics, INC. | $31.77 | 2019 | |
| Mallinckrodt Enterprises LLC | $31.71 | 2019 | |
| Biocodex, INC. | $29.90 | 2023 | Diacomit |
| Aucta Pharmaceuticals, INC. | $29.37 | 2024 | Motpoly Xr |
| Azurity Pharmaceuticals, INC. | $26.25 | 2023 | Eprontia |
| Revance Therapeutics, INC. | $23.63 | 2024 | Daxxify |
| Abbott Laboratories | $22.49 | 2025 | Jot Dx |
| Lilly USA, LLC | $20.56 | 2024 | Amyvid |
| Csl Behring | $20.45 | 2025 | Privigen, Hizentra |
| Noven Therapeutics, LLC | $20.11 | 2023 | Xelstrym |
| Upsher-Smith Laboratories LLC | $17.24 | 2020 | |
| Alnylam Pharmaceuticals INC. | $15.87 | 2025 | Onpattro |
| Mallinckrodt Hospital Products INC. | $14.83 | 2020 | |
| Harmony Biosciences LLC | $14.53 | 2021 | |
| Ge Healthcare | $14.24 | 2024 | |
| Cycle Pharmaceuticals INC | $8.64 | 2024 | Tascenso Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Gossett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.